Compare BEP & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEP | RDY |
|---|---|---|
| Founded | 1999 | 1984 |
| Country | Canada | India |
| Employees | 5870 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 11.6B |
| IPO Year | N/A | 2001 |
| Metric | BEP | RDY |
|---|---|---|
| Price | $34.18 | $13.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $35.70 | $16.90 |
| AVG Volume (30 Days) | 975.3K | ★ 3.1M |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.71% | 0.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.09 | $7.72 |
| Revenue Next Year | N/A | $3.50 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.64 | $12.19 |
| 52 Week High | $35.97 | $16.17 |
| Indicator | BEP | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 54.00 | 50.37 |
| Support Level | $32.05 | $12.90 |
| Resistance Level | $34.91 | $14.06 |
| Average True Range (ATR) | 0.88 | 0.26 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 71.49 | 72.51 |
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners and Brookfield Renewable Corp.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.